Evolus (EOLS) Stock News

Evolus (NASDAQ: EOLS) has received EU Medical Device Regulation certification for four Estyme® injectable hyaluronic acid gels, marking its entry into the dermal filler segment. This certification doubles the company's addressable market outside the U.S. to $1.8 billion. The products, branded as Evolysse™ in the U.S., utilize proprietary cold technology and breakthrough cross-linking technology. Evolus plans a experience program with select physicians in Europe, followed by a broader launch in the second half of 2025. U.S. approval and launch of Evolysse™ remains on track for 2025.

Evolus announced significant milestones for its Evolus Rewards™ patient loyalty program, surpassing 1 million enrolled consumers and achieving 2 million Jeuveau® redemptions. The SMS-based program, launched in 2020, offers patients $40 off Jeuveau® treatments every 90 days at participating providers. The company plans to launch Club Evolus™, the industry's first subscription-based consumer membership program from a neurotoxin manufacturer, on November 4, 2024. Notably, more than half of new program entrants are millennials or younger, and participating practices experience significantly higher revenue growth compared to non-participating practices.

Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its third quarter 2024 financial results release for November 6, 2024, after U.S. market close. Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Investors can join via phone or webcast through the company's Investor Relations page.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of stock options and restricted stock units (RSUs) to newly hired employees. The company granted:

- Non-qualified stock options to purchase 10,251 shares and 31,049 RSUs to 16 new non-executive employees

- Individually negotiated awards to Umberto La Magna, Senior VP, International, including options to purchase 40,286 shares and 28,213 RSUs

These awards, approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, have a grant and vesting commencement date of October 7, 2024. The stock options have an exercise price of $16.49 per share, a 10-year term, and vest over 4 years with 25% vesting annually. RSUs also vest 25% annually over 4 years.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has reported the grant of 10,845 restricted stock units (RSUs) to 5 newly hired non-executive employees. The awards were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date of September 12, 2024, and a vesting commencement date of September 7, 2024.

The RSUs are designed to vest 25% on each annual anniversary of the vesting commencement date. These grants serve as an inducement for new employees joining Evolus, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the RSU agreement, including continuous employment requirements on each vesting date.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will ring the Nasdaq closing bell on Friday, September 13, 2024. The ceremony, taking place at the Nasdaq MarketSite in Times Square, New York City, will be led by CEO David Moatazedi and the company's leadership team. This event celebrates Evolus' five-year anniversary as a publicly traded company and follows their recent investor day on September 12th.

Moatazedi highlighted the company's transformation from a single-product aesthetics company to a multi-product performance beauty innovator. The live broadcast of the ceremony will begin at 3:45 p.m. Eastern Time, and management will participate in a Behind the Bell interview before the event.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of restricted stock units (RSUs) and stock options to newly hired non-executive employees. In July, 46,363 RSUs were granted to 16 employees. In August, 35,921 RSUs and options to purchase 18,097 shares were granted to 10 employees. The August stock options have an exercise price of $12.91 per share and a 10-year term. Both RSUs and options vest over 4 years, with 25% vesting annually. These grants were approved under Evolus' 2023 Inducement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for new employees.

Evolus (NASDAQ: EOLS) reported strong Q2 2024 results, with total net revenue of $66.9 million, up 36% year-over-year. The company raised its full-year 2024 net revenue guidance to $260-$270 million, representing up to 34% growth. Evolus achieved its first-ever quarter of profitability with positive non-GAAP operating income of $1.1 million. Key highlights include:

- Added 770 new customer accounts, totaling ~14,000 since launch
- Evolus Rewards program grew to over 900,000 members
- Submitted PMA application to FDA for Evolysse™ Lift and Smooth fillers
- Launched Nuceiva® in Spain
- Expects approval and launch of fillers in H2 2025
- Projects total net revenue to reach at least $700 million by 2028

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has announced its upcoming Investor Day scheduled for September 12, 2024 in New York City. The event will be held at the "SECOND Floor" venue and will offer both in-person and webcast participation options. Starting at 7:30 a.m. ET with breakfast, formal presentations will begin at 8:00 a.m. ET and conclude by 12:00 p.m. ET.

During the event, Evolus' management team will provide detailed insights into the company's strategic vision, investment strategies, growth levers, and financial outlook. The presentations will be followed by a Q&A session. Pre-registration is required for both in-person and webcast attendees. A replay of the webcast and supporting materials will be made available on the Evolus website after the event.